Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL) has a cash flow conversion efficiency ratio of 0.018x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (TL174.79 Million ≈ $3.91 Million USD) by net assets (TL9.76 Billion ≈ $218.58 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GENIL equity financing ratio to measure how much of total assets are equity-financed.
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Gen Ilac ve Saglik Urunleri Sanayi ve Ti's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangxi Guoguang Commercial Chains Co Ltd
SHG:605188
|
0.036x |
|
Shantou Dongfeng Printing Co Ltd
SHG:601515
|
-0.004x |
|
Sheela Foam Limited
NSE:SFL
|
0.038x |
|
Changyuan Group Ltd
SHG:600525
|
0.048x |
|
Haima Automobile Group Co Ltd
SHE:000572
|
0.037x |
|
São Martinho S.A
SA:SMTO3
|
0.286x |
|
Guangxi Wuzhou Communications Co Ltd
SHG:600368
|
0.038x |
|
Barrett Business Services Inc
NASDAQ:BBSI
|
0.160x |
Annual Cash Flow Conversion Efficiency for Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (2018–2024)
The table below shows the annual cash flow conversion efficiency of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Gen Ilac ve Saglik Urunleri Sanayi ve Ti.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | TL7.31 Billion ≈ $163.67 Million |
TL1.99 Billion ≈ $44.65 Million |
0.273x | +647.34% |
| 2023-12-31 | TL7.01 Billion ≈ $157.11 Million |
TL256.05 Million ≈ $5.73 Million |
0.037x | +533.85% |
| 2022-12-31 | TL2.80 Billion ≈ $62.81 Million |
TL16.15 Million ≈ $361.73K |
0.006x | -95.34% |
| 2021-12-31 | TL1.28 Billion ≈ $28.76 Million |
TL158.83 Million ≈ $3.56 Million |
0.124x | -30.18% |
| 2020-12-31 | TL557.36 Million ≈ $12.48 Million |
TL98.74 Million ≈ $2.21 Million |
0.177x | -73.86% |
| 2019-12-31 | TL245.48 Million ≈ $5.50 Million |
TL166.39 Million ≈ $3.73 Million |
0.678x | +270244.50% |
| 2018-12-31 | TL112.59 Million ≈ $2.52 Million |
TL28.23K ≈ $632.21 |
0.000x | -- |
About Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV… Read more